PharmaEssentia Appoints Fred Paster as Head of Commercial

BURLINGTON, Mass.–(BUSINESS WIRE)–PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Fred Paster as Head of Commercial. 

Fred is a seasoned healthcare industry business leader who has overseen research and business development pipelines across oncology, specialty and rare diseases to commercial success, with experience across the United States, Europe, Latin America and Asia. As the new Head of Commercial at PharmaEssentia, Fred will be responsible for the strategic growth of PharmaEssentia USA’s capabilities and collaborations to enable transformative healthcare solutions for patients with challenging diseases in the areas of hematology, oncology and immunology. In his role, Fred will lead the commercial teams, including sales, marketing and analytics.

“Fred has extensive experience at premier pharmaceutical organizations growing pipelines and overseeing products across their lifecycles, and we are thrilled to welcome him to PharmaEssentia to help drive another commercial growth and success,” said Dr. Ko-Chung Lin, PharmaEssentia Founder and Chief Executive Officer. “This is an exciting time in our Company’s growth, as we advance our commitment to provide new therapeutic solutions for patients with myeloproliferative neoplasms and other hematological diseases that have limited therapeutic options.”

Before coming to PharmaEssentia, Fred has a proven track record as a leader in the healthcare industry with experience across the United States, Europe, Latin America, and Asia, including serving in leadership posts for Alexion Pharmaceuticals, Takeda Oncology and Takeda Pharma International. Fred also has held multiple commercial and marketing positions with Millennium Pharmaceuticals, The Medicines Company and Boston Consulting Group. Fred received his M.S. and B.S. at Massachusetts Institute of Technology and M.B.A. at Harvard Business School. He is also a Chartered Financial Analyst (CFA) charterholder.

About PharmaEssentia

PharmaEssentia (TWSE: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

For more information about PharmaEssentia USA, visit the websiteLinkedIn or Twitter.